Boston’s biotech industry, once a vibrant sector, is currently experiencing a significant downturn marked by a drop in venture capital funding and government support, leading to layoffs and a tough job market.
According to a report from the Wall Street Journal, the biotech sector, which has been a crucial economic player in this affluent region, is facing serious challenges. The decline in venture capital and reduced government research funding have contributed to job losses, making the job search particularly tough for those in the industry.
Many individuals, like Jeremy Liu, 31, who relocated from New Jersey to Boston in 2018 for his Ph.D., find the job market especially daunting. Liu, who earned a master’s degree in chemistry from the University of Massachusetts Boston last year, has applied to around 500 jobs without success. He’s even considering looking for opportunities abroad. “People have suggested I think about applying to China because their industry is really thriving right now,” Liu noted.
The job landscape looks bleak. After years of growth, even during the pandemic, Massachusetts saw a small decline in biotech research and development jobs to about 65,000 in 2024. Federal data indicates that job losses will likely persist through at least June, with employment figures remaining low. By late September, estimates indicated that nearly 28% of laboratory space in metropolitan Boston was unoccupied, according to real estate experts at CBRE.
This economic downturn presents notable challenges for a region where high-paying jobs have historically helped mitigate high living costs. Massachusetts is also facing fierce competition from other states trying to lure talent and investment away from the area.
Governor Maura Healey of Massachusetts acknowledged in a recent interview that “the state and the country are competing against us every day.” In late October, Healey advocated for a $400 million Competitiveness Plan during a state Legislature hearing, aimed at encouraging new investments and replacing lost research funds. This proposal is currently under review by lawmakers.
Biotechnology plays a vital role in Boston’s economy, with major companies and startups positioned near universities that produce both research and prospective workforce. Developers had invested heavily in new spaces during the pandemic, anticipating ongoing demand, but much of this has remained unoccupied as the industry has cooled.
As per MassBio, venture capital investment has sharply declined, reaching the lowest levels since 2017 in the first half of 2025. Moreover, significant cuts to active research funding were made by the Trump administration this year. Historically, states like Massachusetts have received substantial NIH funding per capita, but the agency has recently indicated plans to distribute grants more evenly across the country.
The impacts of these shifts are visible on the ground. In Kendall Square, which is Cambridge’s key life sciences hub aside from MIT, lab vacancy rates soared to 17% in September, compared to a mere 0.4% in 2021. Several restaurants that catered to biotech workers have shut down, while financially-strapped startups are trimming staff and consolidating operations.
In another turn of events, Boston’s Democratic Mayor Michelle Wu has attributed the city’s success to the Somali community. At a recent news conference, she stated that the approximately 8,000 Somali immigrants in the Boston area are integral to the community, serving as doctors, nurses, teachers, and first responders. “You can’t discuss Boston’s achievements in safety, jobs, and education without recognizing the Somali community that drives the city,” Wu remarked, expressing gratitude towards her Somali-American neighbors.
read more of the Wall Street Journal here.
